Tilray Brands Inc (2HQ.BE)
| Previous close | 1.8105 |
| Open | 1.7655 |
| Bid | 1.7505 x 0 |
| Ask | 1.7635 x 0 |
| Day's range | 1.7655 - 1.7655 |
| 52-week range | 1.3930 - 3.0520 |
| Volume | |
| Avg. volume | 812 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Market Exclusive
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Ayr Wellness reported solid first quarter results. Cresco Labs reported stagnant sales but an optimistic outlook for 2024. Tilray announced a $250 million equity offering to fund U.S. asset acquisitions amid legalization optimism. Flora Growth is strategizing on cannabis reform to its reverse financial trend. Key Takeaways; Psychedelic Sector Enveric Biosciences […]
- Yahoo Finance Video
Tilray preps for marijuana reclassification, may sell stock
Shares of Tilray Brands (TLRY) fell sharply on Friday after filing to offer up to $250 million worth of additional shares. The company says the funds would be used to make acquisitions or other investments, not for general purposes. Tilray says it is positioning itself to be ready for the potential reclassification of marijuana, something President Biden voiced support for on Thursday. Yahoo Finance's Julie Hyman and Josh Lipton recap the latest developments for Tilray. This post was written by Stephanie Mikulich.
- Reuters
Cannabis stocks rally after DOJ proposal to reclassify marijuana
Cannabis stocks including Tilray, Curaleaf, and the AdvisorShares Pure US Cannabis ETF rallied on Thursday after the U.S. Department of Justice unveiled a historic proposal to ease restrictions on marijuana. Under the proposal, cannabis would be reclassified from a so-called Schedule I drug, which are considered highly additive with no medical benefits, to a Schedule III, signifying it has moderate to low potential for physical and psychological dependence. "No safety concerns were identified in the FDA's review that would indicate that medical use of marijuana poses unacceptably high safety risks," the proposal says.
